Galmed Pharmaceuticals
$0.5625
28
-$0.09-13.17% 08:42 Today
Statistics
Day High
0.5704
Day Low
0.5704
52W High
2.34
52W Low
0.411
Volume
140
Avg. Volume
-
Mkt Cap
4.38M
P/E Ratio
-
Dividend Yield
-
Dividend
-
Upcoming
Earnings
30JulExpected
Expected EPS
-0.39
Actual EPS
N/A
Financials
-Profit Margin
Unprofitable0Revenue
-10.31MNet Income
People Also Follow
This list is based on the watchlists of people on Stock Events who follow GLMD. It's not an investment recommendation.
Competitors
This list is an analysis based on recent market events. It's not an investment recommendation.
Madrigal Pharmaceuticals
MDGL
Mkt Cap11.73B
Viking Therapeutics
VKTX
Mkt Cap4.35B
Gilead Sciences
GILD
Mkt Cap162.98B
Agios Pharmaceuticals
AGIO
Mkt Cap2.25B
Novartis
NVS
Mkt Cap305.1B
Abbvie
ABBV
Mkt Cap461.26B
Pfizer
PFE
Mkt Cap138.61B
Merck
MRK
Mkt Cap319.99B
About
Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases and related indications. The company develops Aramchol, a first-in-class synthetic fatty acid-bile acid conjugate molecule which is in a Phase III study for oral treatment for non-alcoholic steato-hepatitis (NASH) in patients who are overweight or obese and have prediabetes or type II diabetes mellitus. The company also evaluates Aramchol through the ARRIVE Study, a Phase IIa clinical trial with HIV-associated non-alcoholic fatty liver disease and lipodystrophy. In addition, it engages in the development of Amilo-5MER, a 5 amino acid synthetic peptide methionine, threonine, alanine, aspartic acid, and valine. Further, the company is developing MyBiotics, which is in pre-clinical trials for NASH and fibrosis. It has a license agreement with Samil Pharma. Co., Ltd. for the commercialization of Aramchol in the Republic of Korea; and a collaboration agreement with OnKai for its AI platform and Tissue Dynamics to develop a novel human chronic cardiac fibrosis model. Galmed Pharmaceuticals Ltd. was founded in 2000 and is headquartered in Ramat Gan, Israel.
Show more...
CEO
Mr. Allen Baharaff
Employees
5
Country
Israel
ISIN
IL0011313900
Listings
0 Comments
Share your thoughts
FAQ
What is Galmed Pharmaceuticals stock price today?▼
The current price of GLMD is $0.56 USD — it has decreased by -13.17% in the past 24 hours. Watch Galmed Pharmaceuticals stock price performance more closely on the chart.
What is Galmed Pharmaceuticals stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Galmed Pharmaceuticals stocks are traded under the ticker GLMD.
Is Galmed Pharmaceuticals stock price growing?▼
GLMD stock has fallen by -0.09% compared to the previous week, the month change is a -18.05% fall, over the last year Galmed Pharmaceuticals has showed a -68.49% decrease.
What is Galmed Pharmaceuticals market cap?▼
Today Galmed Pharmaceuticals has the market capitalization of 4.38M
When is the next Galmed Pharmaceuticals earnings date?▼
Galmed Pharmaceuticals is going to release the next earnings report on July 30, 2026.
What were Galmed Pharmaceuticals earnings last quarter?▼
GLMD earnings for the last quarter are -0.33 USD per share, whereas the estimation was -0.54 USD resulting in a +38.89% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Galmed Pharmaceuticals revenue for the last year?▼
Galmed Pharmaceuticals revenue for the last year amounts to 0 USD.
What is Galmed Pharmaceuticals net income for the last year?▼
GLMD net income for the last year is -10.31M USD.
How many employees does Galmed Pharmaceuticals have?▼
As of July 06, 2026, the company has 5 employees.
In which sector is Galmed Pharmaceuticals located?▼
Galmed Pharmaceuticals operates in the Health & Wellness sector.
When did Galmed Pharmaceuticals complete a stock split?▼
The last stock split for Galmed Pharmaceuticals was on August 30, 2024 with a ratio of 1:12.
Where is Galmed Pharmaceuticals headquartered?▼
Galmed Pharmaceuticals is headquartered in Ramat Gan, Israel.